Olaya VA, Bustamante OJC

Language: Spanish
References: 8
Page: 121-123
PDF size: 166.15 Kb.

Text Extraction

No abstract.

REFERENCES

1. Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M.,Bittencourt, H., … & Grupp, S. A. Tisagenlecleucel in childrenand young adults with B-cell lymphoblastic leukemia.New England Journal of Medicine. 2018; 378(5):439-448

2. Gust, J., Finney, O. C., Li, D., Brakke, H. M., Hicks, R. M.,Futrell, R. B., … & Jensen, M. C. Glial injury in neurotoxicityafter pediatric CD19-directed chimeric antigen receptorT cell therapy. Annals of Neurology. 2020; 88(5):726-739.

3. Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L.,Rheingold, S. R., … & June, C. H. Chimeric antigen receptor–modified T cells for acute lymphoid leukemia. NewEngland Journal of Medicine. 2013; 368(16):1509-1518.

4. Schuster, S. J., Svoboda, J., Chong, E. A., Nasta, S. D., Mato,A. R., Anak, Ö., … & Porter, D. L. Chimeric antigen receptorT cells in refractory B-cell lymphomas. New EnglandJournal of Medicine. 2019; 377(26):2545-2554.

5. Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M.,Cui, Y. K., Delbrook, C., Feldman, S. A., … & Rosenberg,S. A. T cells expressing CD19 chimeric antigen receptorsfor acute lymphoblastic leukaemia in children and youngadults: A phase 1 dose-escalation trial. The Lancet Oncology.2020;21(1):59-71.

6. Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J.,Miklos, D. B., Jacobson, C. A., … & Westin, J. R. Axicabtageneciloleucel CAR T-cell therapy in refractory largeB-cell lymphoma. New England Journal of Medicine. 2018;377(26): 2531-2544.

7. Sadelain, M. Chimeric antigen receptors: Driving immunologytowards synthetic biology. Current Opinion inImmunology. 2017; 47:112-120

8. Miller, I. C., & Sadelain, M. CAR T cell therapy: Currentlimitations and potential strategies. Nature Reviews ClinicalOncology. 2023; 20(2):75-91.